Reduction in vertebral fractures with raloxifene

The cumulative proportion of women with at least one incident VFx at four years. Women with or without prevalent VFxs and who had a baseline and any follow-up radiograph were treated with placebo, or raloxifene 60 mg/day or 120 mg/day.
(A) Total study population (n = 6828).
(B) Women (n = 5077) who reported no use of other bone-active agents in year 4. The numbers above each bar indicate the number of women in each group who had a new VFx.